In the News
- January 2021: Glaucoma and Genetics Come Into Focus
- December 2020: Dr. John received the Sanford and Susan Greenberg Visionary Prize to End Blindness 20/20
Please read more at the following links:
- PR Newswire
- Columbia University Department of Ophthalmology
- People Magazine
- National Geographic (subscription required)
- Awards Ceremony
- New metabolic treatment strategies for glaucoma: Paper published in Proceedings of the National Academy of Sciences (PNAS). We discover further metabolic disturbances that contribute to glaucoma vulnerability. We expand the treatment options by showing that both pyruvate or rapamycin are protective against glaucoma. This builds on our concept of metabolic and resilience boosting treatments.
- December 2019: Simon John joins the Department of Ophthalmology at Columbia University
- April 2018: An Eye for Research
- May 2017: Preserving Metabolic Function in Glaucoma
Further work from the John lab demonstrating that metabolism supporting, Resilence-based treatments are effectice against glaucoma. We that treatment with vitamin B3 enhances the effects of gene-based therapeutic interventions and protects from all assessed measures of glaucoma.
- April 2017: Providing a Clearer View On Glaucoma Processes
Paper published in Proceedings of the National Academy of Sciences (PNAS) suggests that immune changes occur very early following IOP elevation and prior to any detected retinal ganglion cell dysfunction. The research provides evidence that astrocytes protect retinal ganglion cells during periods of increased pressure in the eye via a pathway involving complement C3.
- February 2017: Vitamin B3 Prevents Glaucoma
A breakthrough paper demonstrating metabolic abnormalities in glaucoma. We show that NAD boosting treatments, including gene therapy, are potently protective in an inherited mouse model of glaucoma. This work led to the concept of Resilience-boosting treatments that enhance bioenergetic and other cellular resources to prevent glaucoma.